MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202511113511 A) filed by Eras Lucknow Medical College & Hospital; American University Of Barbados; Mr. Mohsin Ali Khan; Mr. Zaw Ali Khan; Ms. Kinza Zehra; and Ms. Sarina Zehra, Lucknow, Uttar Pradesh, on Nov. 18, 2025, for 'alzheimers disease.'
Inventor(s) include Mr. Mohsin Ali Khan; Mr. Zaw Ali Khan; Ms. Kinza Zehra; and Ms. Sarina Zehra.
The application for the patent was published on Jan. 9, under issue no. 02/2026.
According to the abstract released by the Intellectual Property India: "The advanced personalized molecular treatment framework introduces an innovative multi-targeted therapeutic intervention system for comprehensive Alzheimer's disease management that integrates molecular profiling protocols with adaptive biomarker determination mechanisms, facilitating real-time pathway modulation, dynamic therapeutic optimization, and robust treatment confirmation while maintaining seamless clinical integration and therapeutic efficacy for consistent neurodegenerative disease applications. [510] The comprehensive molecular framework employs adaptive biochemical algorithms and precision biomarker protocols, utilizing embedded computational processing arrays and natural compound optimization systems to ensure timely molecular target identification, enhanced neuroprotective understanding, and optimal therapeutic reliability while maintaining continuous pathway monitoring capabilities through validated clinical assessment tools including Mini-Mental State Examination scoring and functional disability evaluations. [515] The integrated methodology combines multi-dimensional molecular techniques with artificial intelligence-driven pathway recognition systems, leveraging variable-precision biomarker signals and multi-factor molecular indicators to optimize therapeutic procedures and treatment workflows for maximum neuroprotective accuracy and minimal therapeutic uncertainty during critical neurological applications, as demonstrated through progressive MSSE score improvements from baseline measurements. [520] The novel responsive therapeutic architecture features engineered high-precision molecular components with specialized pathway fingerprinting protocols, enabling complex multi-stage therapeutic verification while ensuring treatment consistency and performance optimization across various clinical instruments without compromising system reliability, validated through longitudinal cognitive assessment data showing measurable therapeutic progression. [525] The innovative design incorporates strategic validation mechanisms for enhanced molecular identification and therapeutic security, utilizing optimized multi-compound systems and adaptive treatment technology to ensure legitimate therapeutic assignment while maintaining functionality across diverse clinical environments and treatment scenarios, supported by comprehensive functional assessment protocols. [530] Implementation methodology emphasizes scalable molecular integration and efficient therapeutic sequences, implementing interactive biomarker measures and pathway recognition algorithms to achieve superior molecular determination, enhanced therapeutic identification, and unauthorized treatment prevention while ensuring technological simplicity during clinical monitoring through standardized cognitive evaluation frameworks. [535] The system demonstrates exceptional adaptability through comprehensive integration of molecular identification protocols and intelligent therapeutic technologies, validating its effectiveness across various multifunctional treatment configurations and clinical scenarios while maintaining consistent therapeutic performance and operational efficiency under diverse conditions, as evidenced by sustained cognitive improvement trajectories. [540] The developed framework enables sustainable and reliable treatment of neurodegenerative diseases through streamlined, AI-powered molecular systems, providing significant advantages over traditional therapeutic approaches through variable validation mechanisms, adaptive identification protocols, and improved molecular assignment while maintaining superior therapeutic accuracy during critical clinical treatment procedures, demonstrated through measurable cognitive score enhancements and functional capacity improvements."
Disclaimer: Curated by HT Syndication.
